Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Non-cash Items (2016 - 2025)

Collegium Pharmaceutical has reported Non-cash Items over the past 10 years, most recently at $66.2 million for Q3 2025.

  • Quarterly results put Non-cash Items at $66.2 million for Q3 2025, up 9584.06% from a year ago — trailing twelve months through Sep 2025 was $66.2 million (up 9584.06% YoY), and the annual figure for FY2024 was $6.6 million, up 472.78%.
  • Non-cash Items for Q3 2025 was $66.2 million at Collegium Pharmaceutical, up from $583400.0 in the prior quarter.
  • Over the last five years, Non-cash Items for COLL hit a ceiling of $82.4 million in Q1 2025 and a floor of $583400.0 in Q2 2025.
  • Median Non-cash Items over the past 5 years was $13.3 million (2023), compared with a mean of $29.8 million.
  • Peak annual rise in Non-cash Items hit 9584.06% in 2025, while the deepest fall reached 98.88% in 2025.
  • Collegium Pharmaceutical's Non-cash Items stood at $6.1 million in 2021, then soared by 31.02% to $8.0 million in 2022, then surged by 67.19% to $13.3 million in 2023, then crashed by 50.11% to $6.6 million in 2024, then skyrocketed by 898.6% to $66.2 million in 2025.
  • The last three reported values for Non-cash Items were $66.2 million (Q3 2025), $583400.0 (Q2 2025), and $82.4 million (Q1 2025) per Business Quant data.